Exenatide, an exendin-4based GLP-1 agonist, comes in both twice-daily and once-weekly formulations and was among the earliest GLP-1 drugs approved for diabetes before weight loss applications became prominent
Of these, 1,956 gastrointestinal reports were for exenatide (9.19%), 2,891 for liraglutide (13.58%), 10,757 for dulaglutide (50.55%), 182 for lixisenatide (0.86%), and 5,567 (26.16%) for semaglutide ( Figure 1 )
Frequently Asked Questions What are the business opportunities for Glutathione 600mg + Vitamin C I.P
10.1007/s12010-024-04879-6 [DOI] [PubMed] [Google Scholar] Song J., Gao X., Tang Z., Li H., Ruan Y., Liu Z., et al
Central Hudson Gas and Electrics 2025 DSIP: Main Document | Appendices 2025 Marginal Cost of Service (MCOS) Study Consolidated Edisons 2025 DSIP: Complete Document 2025 MCOS Study 2025 Benefit Cost Analysis (BCA) Handbook National Grids 2025 DSIP: Complete Document 2025 MCOS Study NYSEG and RG&Es 2025 DSIP: Complete Document 2025 MCOS Study O&Rs 2025 DSIP: Complete Document 2025 MCOS Study 2025 BCA Handbook
For the various analyses, Kaplan-Meier curves are presented in Supplemental Figure S1
